
Expres²ion's core platform patent allowed in Canada

Expres²ion Biotech Holding AB and its affiliate Expres²ion Biotechnologies ApS ("Expres²ion") announce that the Company's patent application "Improved Protein Expression System", that covers the entire Expres² platform, has been allowed in Canada and will be granted with expiry June 12, 2029.

"With the patent allowance in Canada, Expres²ion has now successfully obtained patent protection of its Expres² platform in all major markets of interest. Thereby the major initial goal for our Expres² platform patent portfolio, which is fundamental to our business, has been reached," says Dr. Steen Klysner, CEO of Expres²ion.

The patent application "Improved Protein Expression System" has been filed in 15 different countries covering the Company's major markets. The patent has been issued in the United States, South Korea, Japan, Australia, China, India, and validated in several EU countries following approval by the European Patent Office.

Certified Adviser

Sedermora Fondkommission is appointed as Certified Adviser for Expres²ion.

For further information about Expres²ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: sk@expres2ionbio.com

This press release contains information that Expres²ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on May 17, 2017.

About Expres²ion

Expres²ion Biotechnologies ApS is a fully owned Danish subsidiary of Expres²ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, Expres², that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, Expres²ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.